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Introduction
Classical mitochondrial diseases result from defects of the mitochondrial oxidative phosphorylation pathway (OXPHOS). They present with diverse clinical features [1] . Liver failure however is frequently reported in severe pediatric cases [2] . Its mitochondrial origin is often diagnosed by the presence of defective OXPHOS activities in liver. However, because of the possibility of improper sample preservation or nature, the diagnosis cannot solely rely on these defects but requires identification of the genetic cause of the disease. That identification has recently been tremendously facilitated by next generation sequencing.
Genetic causes of mitochondrial liver failure may be classified with respect to the type of OXPHOS defect. The most frequent are combined defects involving OXPHOS complexes with mitochondrial DNA (mtDNA)-encoded subunits, caused often by mtDNA depletion (profound decrease of the mtDNA amount) [3] [4] [5] [6] or defects of the mtDNA translation [7] [8] [9] . In this group liver functions are globally altered associating synthesis failure with coagulopathy, cytolysis, and cholestasis often progressing towards cirrhosis. These diseases are often multisystem disorders, associating neurological deficits to the liver failure.
Much rarer cases of liver failure have been associated with an isolated OXPHOS defect, which is most often respiratory complex III (ubiquinol cytochrome c oxidoreductase, EC 1.10.2.2). In these cases the liver alterations seemed to differ according to the causal gene.
Global liver failure, resembling that observed with multiple OXPHOS defects, has been described in severe, early onset, diseases due to mutations of BCS1L gene encoding a complex III assembly factor [10, 11] , acute episodes of hypoglycemia and hyperammonemia have been associated with mutations of UQCRB, CYC1 and UQCRC2 genes encoding complex III structural subunits [12] [13] [14] , and normal liver functions have been reported in diseases due to mutations of genes encoding either complex III assembly factors (TTC19 [15] , UQCC2 [16] , UQCC3 [17] and LYRM7 [18, 19] ) or structural subunits (MT-CYB [20] , UQCRQ [21] ). The role of complex III in liver function thus appears disputable.
We here report a patient with liver complex III defect. Although exome sequencing revealed two genes, MTO1 and LYRM7, both carrying homozygous truncating mutations and both encoding essential mitochondrial proteins, functional complementation by lentiviral vectors demonstrated that the LYRM7 mutations were causing the complex III defect. Comparison of the patient's clinical history to previously reported patients with complex III defect, some actually followed by us, led us to propose common pathophysiology for several complex III defects whereby profound complex III defect in liver does not induce actual liver failure but impedes liver adaptation to prolonged fasting. Lack of appropriate metabolic treatment of the fasting-induced lactic acidosis, hypoglycemia, and hyperammonemia may result in irreversible brain damage.
Material, patient and methods

Patient
The patient was the third child of first cousins parents. She first presented at 6 months of age with ketoacidosis, hyperglycemia and glycosuria. Intravenous injection of insulin induced hypoglycemia without correcting ketonuria. The child was transferred to La Rabta hospital in Tunis. At her arrival she was hypotonic, polypneic and presented with mild hepatomegaly.
Biological tests revealed compensated metabolic acidosis (pH 7.42, bicarbonate 15.7 mM, pCO2 24 mmHg), hyperlactatemia (5.2 mM), and hyperlactatorrachia (8 mM) with mild hyperammonemia (64 µM, N<50), but normal liver enzymes and coagulation factors. Very high lactate, 3 OH butyrate and 2-ketoglutarate were found on urinary organic acids profiling.
Electrocardiogram, echocardiography, kidney functions, and electroencephalogram were normal.
The further disease course was marked by episodes of metabolic crises associating metabolic acidosis with hyperlactatemia, ketonuria and hypoglycemia; ammonia was not measured. A severe episode, lasting three days and associated with coma, occurred at one year of age. It was followed by irreversible neurological damage with loss of contact, profound axial hypotonia, peripheral hypertonia, horizontal nystagmus, and deglutition troubles. Hepatic and skin biopsies were performed at that period. The child died shortly afterwards during a recurrent metabolic crisis at 20 months of age.
Samples
All analyses were performed after written informed consent from the parents of the child according to the local institution rules. A needle liver biopsy was immediately frozen in liquid nitrogen, stored at -80°C until enzymatic assays. Primary fibroblasts were derived from a forearm skin biopsy as described in [22] .
DNA samples were obtained from liver and fibroblasts using standard procedure with SDS and proteinase K digestion followed by phenol extraction and isopropanol precipitation. DNA samples from blood were obtained using QiaAmp DNA minikit (Qiagen, Courtaboeuf, France). RNA samples from fibroblasts were obtained using the miRNeasy kit (Qiagen, Courtaboeuf, France).
Mitochondrial fractions were prepared from 2 T175 fibroblasts flasks according to [23] .
Mitochondrial activities
Spectrophotometric assays for the respiratory complexes I, II, III and IV, as well as citrate synthase activities were performed according to [24] .
Western blot analysis
Proteins from mitochondrial pellets were separated by blue native polyacrylamide gel electrophoresis [25] or by SDS-PAGE on a linear 4 to 20% gradient polyacrylamide gel (Biorad, Hertfordshire, UK). Antibodies against UQCRC2 and UQCRFS1 were kindly given by Dr Catherine Godinot, France [26] , antibodies against MT-ND1 and against MT-CO2 were produced in our group [27] ; the other antibodies were commercially available: anti-SDHA, anti-ATP5B and anti-LYRM7 were from Abcam (France), anti-MTO1 from Proteintech (USA) and anti-ACTB from Sigma-Aldrich (USA). They were visualized using peroxidaseconjugated secondary antibodies (Sigma-Aldrich, USA) and Pierce™ ECL Western Blotting Substrate (Life Technologies, USA). Western blot signals were recorded on a Fusion ultrasensitive camera platform (Vilber Lourmat, Germany) and quantified using the Fusion attached software. Results were normalized to the control run on the same gel and to complex II, either the whole complex II after blue native gel electrophoresis or SDHA subunit after SDS gel electrophoresis.
Exome sequencing
Exome sequencing and variant filtering was essentially performed as described previously [28] . In brief, coding DNA fragments were enriched with the SureSelect Human All Exon 50Mb V4 Kit (Agilent, Santa Clara, CA, USA) and sequencing was performed on a HiSeq2000 system (Illumina, San Diego, CA, USA). Reads were aligned to the human genome assembly hg19 (UCSC Genome Browser) with Burrows-Wheeler Aligner (BWA, version 0.7. 5) and detection of genetic variation was performed using SAMtools (version 0.1.19), PINDEL (version 0.2.5a7), and ExomeDepth (version 1.0.0). 96.9 % of the target was covered at least 20-fold.
Lentiviral gene transfer
LYRM7 cDNA was purchased from DNASU Plasmid Repository (Clone ID HsCD00514704) and cloned into the pLenti6.3/V5-TOPO vector system (Invitrogen, Life technologies) for subsequent lentiviral-mediated expression in skin fibroblast cell lines using the ViraPower HiPerform Lentiviral TOPO Expression Kit (Invitrogen, Life technologies) [29] . The corresponding MTO1 clone was already available [30] . We also constructed a third lentivirus for expression of the MTO1 cDNA sequence but with Geneticin resistance [31] . Stably transduced fibroblasts were selected using Blasticidin (Invitrogen) and/or Geneticin (SigmaAldrich).
RNA analyses
Reverse transcription of 2 micrograms total RNA was performed with the Transcriptor First strand cDNA synthesis kit (Roche Diagnostics, USA). The cDNA steady-state was quantified using LightCycler 480 SybrGreen master mix (Roche Diagnostics, USA). Serial dilutions of linearized pGEM-T plasmids with the amplification products as insert, allowed absolute quantification of the cDNA in copy numbers per µL. Results were expressed as copy numbers per 1000 ACTB copies.
Statistical methods
Statistics were performed with SigmaPlot 12.5 software. Non parametric tests were used unless the data were shown to have a normal distribution allowing the use of parametric tests.
The numbers given indicate independent measurements. Mean comparisons were performed with Mann and Whitney test or unpaired Student t test. The Holm-Sidak test for multiple comparisons was used to address the relative influence of lentivirus infection, genotype and their interaction.
Results
Complex III defect was present in the patient's liver and fibroblasts
Spectrophotometric assays of the respiratory chain activities in the patient's liver biopsy disclosed a profound defect in complex III (Table 1) . Other mitochondrial activities were either normal or elevated, in particular rotenone sensitive complex I activity, which is highly sensitive to improper preservation. Significant decrease of complex III activity was also observed in cultured skin fibroblasts from the patient but with complex III residual activity higher than in liver, without significant impact on the combined complex II+III activity.
Complex IV activity appeared mildly decreased in fibroblasts, the defect only being significant when complex IV activity was normalized to citrate synthase activity (p=0.031).
Analysis of the OXPHOS composition of fibroblasts by blue native polyacrylamide gel electrophoresis showed that the amount of complex III was decreased while that of complexes I, II, IV and V was close to controls ( Figure 1A ). SDS-PAGE of complex III subunits showed an almost normal amount of UQCRC2 that contrasted with a severe decrease of UQCRFS1 ( Figure 1B ). Unassembled subunits are efficiently degraded by the mitochondrial quality control [32] . UQCRC2 is one of the first subunits assembled to the complex whereas UQCRFS1 is the last subunit added [33] . The observed pattern could therefore suggest either an alteration of UQCRFS1 itself or a complex III assembly defect.
Search for the genetic alteration causing complex III defect disclosed two candidate genes
Direct sequencing of the coding sequences of UQCRFS1 and other genes implicated in human complex III defects (BCS1L, MT-CYB, UQCRB, UQCRQ and CYC1) disclosed only normal sequence or known polymorphisms. We thus turned to whole exome sequencing. Given that the observed pattern was in line with autosomal recessive inheritance and the clinical phenotype was very rare, we focused on genes carrying homozygous or possible compound heterozygous rare variants (Minor Allele Frequency <0.1 % in 5,000 in house controls and the Washington Exome Variant Server). This search identified 22 genes. Two of these genes, LYRM7 and MTO1, encode mitochondrial proteins [34] and variants in both have been linked to OXPHOS defects. Moreover, in both genes, mutations were homozygous predicted truncating variants. In LYRM7 (NM_181705.3) it was a c. Table 2 . LYRM7 encodes for a small mitochondrial protein (104 aminoacids, molecular weight 11.9 kDa) belonging to the LYR family. It has recently been identified as a complex III late assembly factor [35] and found mutated in a severe infantile case of complex III defect with early onset severe encephalopathy and lactic acidosis [18] . MTO1 encodes for a mitochondrial protein (732 aminoacids, molecular weight after mitochondrial processing 74 kDa [36] ), which has been shown to play a role in mitochondrial tRNA post transcriptional modifications [37] . It has first been thought to be involved in human pathology as a potential modifying factor for mtDNA rRNA mutations [38] but was later associated with cases of hypertrophic cardiomyopathy with combined OXPHOS defect and lactic acidosis [36] .
We verified the presence of the LYRM7 and MTO1 mutations by Sanger sequencing and analyzed their segregation within the family (Figure 2 ). For both genes, the mutation was found in a homozygous state in the patient, heterozygous in both her parents as well as in one of her healthy siblings, and absent in her second healthy sibling. Familial analysis thus could not help to exclude one of the two genes.
Complementation assays demonstrated that LYRM7 mutations were causing the complex III defect.
To assess the causal role of the mutation we constructed lentiviral vectors carrying the wild type cDNA sequence of LYRM7 (LYRM7-lentivirus) or MTO1 (MTO1-lentivirus) associated with blasticidin resistance. In order to test the combined effect of the two mutations, we also constructed a third lentivirus carrying the wild type MTO1 cDNA sequence but with neomycin resistance in order to be independently selected from the virus carrying LYRM7 
Discussion
This study exemplifies some of the difficulties encountered with next generation sequencing.
The unbiased and efficient whole exome-next generation sequencing is bound to find numerous homozygous genetic variants in consanguineous families, such as the one herein reported. Filtering is mandatory to reduce the number of candidate genes. Based on bi-allelic variants plus the nature of the mutation and a known mitochondrial function of the encoded protein in our case, it reduced the number of candidate genes to only two, both already associated with OXPHOS defects. Both mutations are predicted to result in protein truncation.
However, the LYRM7 mutation leaves only 17 amino acids unchanged, while the MTO1 mutation leaves a 665 amino acids shortened by 27 amino acids. Western blot analysis showed that LYRM7 protein could not be detected in the patient's samples in contrast to Hypoglycemia and hyperammonemia observed during the metabolic crises of the patients thus reflect altered metabolism and not actual liver insufficiency. Consequently they are completely reversible provided intensive nutritional care restores the metabolism towards a fed state, with concomitant inhibition of β oxidation and gluconeogenesis. These metabolic crises are expected to be less frequent and less severe with increasing age because the period of time when glycogen breakdown suffices for the maintenance of blood glucose progressively increases [39] . That spontaneous improvement with age has been observed with the patients with UQCRB or CYC1 mutations [12, 13] .
Comparison of the clinical presentation of the patient herein reported disclosed a pattern common to several other cases of complex III defect, including the first two patients with LYRM7 mutations [18] , and the patients with UQCRB [12] , CYC1 [13] or UQCRC2 [14] mutations (Table 3 ). All these genes but LYRM7 encode complex III structural subunits without tissue-specific isoform. The sole clinical difference among these diverse complex III defects was the occurrence of encephalopathy in the patients with LYRM7 mutations [18, 19] .
The possibility to maintain brain functions despite the presence of a profound complex III defect is demonstrated by the patients with mutations in UQCRB [12] or CYC1 [13] , two of whom, followed by one of us, have now reached adulthood with normal brain functions.
The mechanism underlying the encephalopathy of patients with LYRM7 mutations is essential.
Indeed it could not be avoided if it were due to the role of LYRM7 in brain whereas it would be at least partially prevented by appropriate intensive metabolic treatment if it were a consequence of the severe metabolic disturbances due the liver defect. The latter mechanism is suggested by the initially normal neurological status of the patients and by the occurrence of encephalopathy as subacute episodes of deterioration, often triggered by febrile illness [18, 19] . The severe metabolic episodes (with blood pH dropping to 6.78 or prolonged coma) observed in our patient and in the first one reported [18] would also fit with a toxic encephalopathy. The patients most recently reported presented however with a different clinical pattern despite similar or identical LYRM7 mutations [19] . They did not present with severe metabolic disturbances, in accordance with their later onset and prolonged survival, but had significant encephalopathy with distinct leukoencephalopathy. However, because of the potential therapy, it would be important to evaluate these patients metabolic status during one of their episodes of subacute encephalopathy before definitely excluding a toxic component to their brain damage.
If the encephalopathy is essentially due to the role of LYRM7 in brain, the genotype/phenotype relationship of LYRM7 mutations would resemble that of BCS1L and TTC19, encoding other complex III assembly factors, where encephalopathy is either constant (TTC19) or very frequent (BCS1L) [40, 41] . In both cases, encephalopathy occurs in the absence of acute metabolic crises. Most importantly, TTC19 mutations spare liver function whereas severe BCS1L mutations induce generalized liver dysfunction, progressing towards cirrhosis. Part of these differences might be explained by the fact that, in contrast to structural subunits, assembly factors are expected to have other functions in addition to their role OXPHOS assembly. Indeed both BCS1L and TTC19 proteins have been involved in other protein-protein interactions [15, 42] . Mutations of UQCC2 [16] and UQCC3 [17] , both encoding complex III assembly factor and associated with human disease, have each been reported only once in very young patients preventing to reliably ascertain their phenotype.
In conclusion: profound complex III defect in liver induces severe lactic acidosis, ketosis, hypoglycemia, and hyperammonemia that occur after prolonged fasting and may induce irreversible brain damage in the absence of intensive metabolic care. with LYRM7 mutations were identified based on the presence of a distinct multifocal leukoencephalopathy [19] . Metabolic crises were not reported in these patients who presented however with one or several episodes of subacute encephalopathy, during which metabolic parameters are not mentioned. Cells were selected during three weeks with the appropriate antibiotics. In each case data were obtained from two independent samples..
